The Newborn Screening session will be discussing reporting, interpretation, follow-up, interstate variability, new additions (the RUSP, process, and interstate variability).
This educational activity is supported by an educational grant from Ultragenyx.
- Understand how the existing NBS program came to be (how did we get here?)
- Recognize the unique aspects of one of the few universal, compulsory public health programs in the United States (where are we now?)
- Apply understanding of strengths and challenges of the current system and disorders screened to new disorders considered for NBS
Shawn McCandless, MD
Children's Hospital Colorado
Shawn McCandless, MD, speaker for this session, is a speaker for Horizon Therapeutics, a researcher for Aardvark Therapeutics, Levo Therapeutics, Ultragenyx and Harmony Therapeutics and a consultant for Levo Therapeutics.
Planners, faculty, and others in control of content (either individually or as a group) have no relevant financial relationships with ineligible companies.
All of the relevant financial relationships listed have been mitigated.
Children’s Hospital Colorado is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Children’s Hospital Colorado designates this Live activity for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
A general certificate of attendance will be available after the completion of the online evaluation. Claim only credit commensurate of your conference attendance.
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Attendance